- Home
- SEER vs ALDX Comparison
SEER vs ALDX Comparison
Compare SEER & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- ALDX
- Stock Information
- Founded
- SEER 2017
- ALDX 2004
- Country
- SEER United States
- ALDX United States
- Employees
- SEER 134
- ALDX N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- ALDX Health Care
- Exchange
- SEER Nasdaq
- ALDX Nasdaq
- Market Cap
- SEER 121.8M
- ALDX 133.7M
- IPO Year
- SEER 2020
- ALDX 2014
- Fundamental
- Price
- SEER $1.84
- ALDX $2.18
- Analyst Decision
- SEER Hold
- ALDX Strong Buy
- Analyst Count
- SEER 1
- ALDX 2
- Target Price
- SEER $3.00
- ALDX $9.50
- AVG Volume (30 Days)
- SEER 174.6K
- ALDX 1.5M
- Earning Date
- SEER 05-13-2025
- ALDX 05-20-2025
- Dividend Yield
- SEER N/A
- ALDX N/A
- EPS Growth
- SEER N/A
- ALDX N/A
- EPS
- SEER N/A
- ALDX N/A
- Revenue
- SEER $14,170,000.00
- ALDX N/A
- Revenue This Year
- SEER $23.54
- ALDX N/A
- Revenue Next Year
- SEER $42.98
- ALDX N/A
- P/E Ratio
- SEER N/A
- ALDX N/A
- Revenue Growth
- SEER N/A
- ALDX N/A
- 52 Week Low
- SEER $1.56
- ALDX $1.14
- 52 Week High
- SEER $2.63
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- SEER 41.77
- ALDX 35.31
- Support Level
- SEER $1.88
- ALDX $1.90
- Resistance Level
- SEER $1.97
- ALDX $2.89
- Average True Range (ATR)
- SEER 0.10
- ALDX 0.22
- MACD
- SEER -0.02
- ALDX 0.09
- Stochastic Oscillator
- SEER 0.00
- ALDX 28.28
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.